Physician

Internal Medicine

Dr. Joseph P. Miletich, MD

Joseph P. Miletich, MD practices Internal Medicine. Joseph Miletich is a published MD as well. He has 70 publications published. The latest was: Thrombophilia as a multigenic disorder.

Publications

Association between a literature-based genetic risk score and cardiovascular events in women.
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.
Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Wom...
Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genom...
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Wome...
Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study.
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and A...
Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study.
Joseph Miletich talks about big Pharma, biotech and the future of Amgen. Interview by Steve Carney.
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
The role of the factor X activation peptide: a deletion mutagenesis approach.
Biosimilars 2.0: guiding principles for a global "patients first" standard.
G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.
Definition of a factor Va binding site in factor Xa.
Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis.
Substitution of asparagine for arginine 347 of recombinant factor Xa markedly reduces factor Va binding.
Factor V Leiden is not a risk factor for myocardial infarction among young women.
G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.
Thrombophilia as a multigenic disorder.
Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.
The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo.
Prevalence of factor V Leiden in accelerated forms of coronary artery disease.
Expression, purification, and characterization of recombinant human factor X.
Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.
Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.
Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.
Inherited thrombophilia: Part 2.
Inherited thrombophilia: Part 1.
Factor XSt. Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein.
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
Inherited predisposition to thrombosis.
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.
Human Protein Z.
The light chain of factor Va contains the activity of factor Va that accelerates protein C activation by thrombin.
Human coagulation factor Va is a cofactor for the activation of protein C.
The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X.
Purification of human brain tissue factor.
Absence of thrombosis in subjects with heterozygous protein C deficiency.
Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy.
Evolution of human von Willebrand factor: cDNA sequence polymorphisms, repeated domains, and relationship to von Willebrand antigen II.
The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of act...
Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.
Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells.
Characterization of the inhibition of tissue factor in serum.
Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII.
Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.
Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine factor Xa affinity chromatography.
Human tissue factor: cDNA sequence and chromosome localization of the gene.
Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein.
Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening.
Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.
Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.
Laboratory diagnosis of protein C deficiency.
Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.
Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.
Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein.
Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase.
Beta protein C is not glycosylated at asparagine 329. The rate of translation may influence the frequency of usage at asparagine-X-cysteine sites.
The relation of conductivity to the binding of thrombin to human platelets.
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.
Properties of the factor Xa binding site on human platelets.
Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder.
Relationships between platelets and coagulation factors in hemostasis.
Interaction of coagulation factor Xa with human platelets.

Schools

Washington Center School of Medicine

Doctors Specialties

Clinical Pathology
Internal Medicine

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Linda M. Gerrits, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard Daifuku, MD
	Dr. Malcolm B. Taw, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen A. Cech, MD
	Dr. Steven Rosenblum, MD
	Dr. Hilda Maldonado, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard C. McCauley, MD